biostudies-literatureUnknown9(12)Oudard S<h4>Importance</h4>Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable.<h4>Objective</h4>To determine whether biweekly cabazitaxel (CBZ), 16 mg/m2 (biweekly CBZ16), plus prophylactic granulocyte colony-stimulating factor (G-CSF) at each cycle reduces the risk of grade 3 or higher neutropenia and/or neutropenic complications (eg, febrile neutropenia, neutropenic infection, or sepsis) compared with triweekly CBZ, 25 mg/m2 (triweekly CBZ25), plus G-CSF (standard regimen).<h4>Design, setting, and participants</h4>A total of 196 patients 65 years or older with progressive mCRPC were enrolled in this prospective phase 3 randomized clinical trial conducted in France (18 centers)JAMA oncology1629-1638https://www.ebi.ac.uk/biostudies/studies/S-EPMC10603579biostudies-literatureBiweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.PMC10603579Saldana CFeyerabend SAmela EVoog EHelissey CSchostak MOudard STran YThiery-Vuillemin ABelhouari HAldabbagh KPhan LPfister DSevin EDi Fiore FHuillard OLange CHouede NBennamoun MHasbini ABesson DKotti SBoegemann MVon Amsberg GQuivy ARatta RBarthelemy PfalseBiweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.<h4>Importance</h4>Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable.<h4>Objective</h4>To determine whether biweekly cabazitaxel (CBZ), 16 mg/m2 (biweekly CBZ16), plus prophylactic granulocyte colony-stimulating factor (G-CSF) at each cycle reduces the risk of grade 3 or higher neutropenia and/or neutropenic complications (eg, febrile neutropenia, neutropenic infection, or sepsis) compared with triweekly CBZ, 25 mg/m2 (triweekly CBZ25), plus G-CSF (standard regimen).<h4>Design, setting, and participants</h4>A total of 196 patients 65 years or older with progressive mCRPC were enrolled in this prospective phase 3 randomized clinical trial conducted in France (18 centers)2023-01-01T00:00:00Z2023 Dec2026-06-01T12:36:28.312Z2025-04-19T17:25:55.275ZS-EPMC106035793788307310.1001/jamaoncol.2023.4255